SUPPLEMENT

Q2 2024 — Non-GAAP reconciliations

Q2 2024PDF · 19 pages280 KB
DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
AND SUPPLEMENTAL FORWARD-LOOKING INFORMATION
THREE AND SIX-MONTH PERIODS ENDED JUNE 28, 2024 AND JUNE 30, 2023

-- 1 of 19 --

TABLE OF CONTENTS
Page
1 Sales (Decline) Growth by Segment and Core Sales (Decline) Growth by Segment
1 Forecasted Core Sales Decline and Adjusted Operating Profit Margin
2 Segment Sales, Operating Profit and Adjusted Operating Profit
3 Non-GAAP Profitability Measures
7 Other Non-GAAP Adjusted P&L Measures
12 Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
13 Operating Profit Margins and Year-Over-Year Core Operating Profit Margin Changes
14 Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations, Operating Cash Flow from Continuing Operations to Net
Earnings from Continuing Operations Ratio and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations
Conversion Ratio
15 Statement Regarding Non-GAAP Measures
FORWARD-LOOKING STATEMENTS DISCLOSURE
Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-
looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ
materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among
other things: unanticipated, further declines in demand for our COVID-19 related products, the impact of global health crises, the impact of our debt obligations on our operations and liquidity,
deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in
our business and products, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions
or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for
improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations
relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health
care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the
anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including
tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data
privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and
changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and
environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual
property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations
and fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel
partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or
regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented
employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts),
disruptions relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual
results to differ materially from these forward-looking statements is available in our SEC filings, including our 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the
second quarter of 2024. These forward-looking statements speak only as of the date of this document (July 22, 2024) and except to the extent required by applicable law, the Company does not
assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

-- 2 of 19 --

% Change Three-Month Period Ended June 28, 2024 vs. Comparable 2023
Period
Segments
Total Company Biotechnology Life Sciences Diagnostics
Total sales (decline) growth (GAAP) (3.0) % (9.0) % (1.5) % 1.5 %
Impact of:
Acquisitions (2.0) % — % (6.0) % — %
Currency exchange rates 1.5 % 2.0 % 2.0 % 1.5 %
Core sales (decline) growth (non-GAAP) (3.5) % (7.0) % (5.5) % 3.0 %
% Change Six-Month Period Ended June 28, 2024 vs. Comparable 2023
Period
Segments
Total Company Biotechnology Life Sciences Diagnostics
Total sales (decline) growth (GAAP) (2.5) % (13.5) % 0.5 % 4.0 %
Impact of:
Acquisitions/divestitures (2.0) % — % (6.5) % — %
Currency exchange rates 1.0 % 1.5 % 1.5 % 1.0 %
Core sales (decline) growth (non-GAAP) (3.5) % (12.0) % (4.5) % 5.0 %
Forecasted Core Sales Decline and Adjusted Operating Profit Margin
The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue,
such as currency translation, acquisitions and divested product lines. Additionally, we do not reconcile forecasted adjusted operating profit margin (or components
thereof) to the comparable GAAP measures because of the difficulty in estimating the other components (in addition to items identified in the prior sentence) such
as investment gains and losses and impairments, which would be reflected in any forecasted GAAP operating profit.
% Change Three-Month Period
Ending September 27, 2024 vs.
Comparable 2023 Period
% Change Year Ending
December 31, 2024 vs.
Comparable 2023 Period
Core sales decline (non-GAAP) -Low-single digit -Low-single digit
Three-Month Period Ending
September 27, 2024 Year Ending
December 31, 2024
Adjusted operating profit margin (non-GAAP) ~26.0% ~29.0%
DANAHER CORPORATION
Sales (Decline) Growth by Segment and Core Sales (Decline) Growth by Segment
1

-- 3 of 19 --

Sales (GAAP)
Biotechnology $ 1,713 $ 1,885 $ 3,237 $ 3,749
Life Sciences 1,770 1,796 3,515 3,505
Diagnostics 2,260 2,231 4,787 4,607
Total Company $ 5,743 $ 5,912 $ 11,539 $ 11,861
Operating Profit (GAAP)
Biotechnology $ 462 $ 480 $ 787 $ 1,076
Life Sciences 233 340 468 661
Diagnostics 556 424 1,386 1,101
Other (83) (81) (161) (158)
Total Company $ 1,168 $ 1,163 $ 2,480 $ 2,680
Amortization of Intangible Assets (GAAP)
Biotechnology $ 214 $ 218 $ 432 $ 435
Life Sciences 140 104 281 209
Diagnostics 48 50 96 100
Total Company $ 402 $ 372 $ 809 $ 744
Other Operating Profit Adjustments 1
Biotechnology $ — $ 42 $ — $ 42
Life Sciences — — 25 —
Diagnostics — — — —
Other — — — —
Total Company $ — $ 42 $ 25 $ 42
Adjusted Operating Profit (non-GAAP) 2
Biotechnology $ 676 $ 740 $ 1,219 $ 1,553
Life Sciences 373 444 774 870
Diagnostics 604 474 1,482 1,201
Other (83) (81) (161) (158)
Total Company $ 1,570 $ 1,577 $ 3,314 $ 3,466
Three-Month Period Ended Six-Month Period Ended
June 28, 2024 June 30, 2023 June 28, 2024 June 30, 2023
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
2 Adjusted Operating Profit (non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined).
DANAHER CORPORATION
Segment Sales, Operating Profit and Adjusted Operating Profit
($ in millions)
2

-- 4 of 19 --

Three-Month Period Ended June 28, 2024
Biotechnology Life Sciences Diagnostics Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 907
Interest, Net 26
Other Nonoperating (Income) Expense 59
Income Taxes 176
Operating Profit (GAAP) $ 462 $ 233 $ 556 $ (83) $ 1,168
Other Operating Profit Adjustments 1 — — — — —
Amortization of Intangible Assets 214 140 48 — 402
Adjusted Operating Profit (Non-GAAP) 676 373 604 (83) 1,570
Depreciation 35 41 100 2 178
Adjusted EBITDA (Non-GAAP) $ 711 $ 414 $ 704 $ (81) $ 1,748
Interest, Net (26)
Other Nonoperating Income (Expense) (59)
Income Taxes (176)
Other Operating Profit Adjustments 1 —
Depreciation (178)
Amortization of Intangible Assets (402)
Net Earnings from Continuing Operations (GAAP) $ 907
Sales (GAAP) $ 1,713 $ 1,770 $ 2,260 $ 5,743
Net Earnings from Continuing Operations Margin (GAAP) 15.8 %
Operating Profit Margin (GAAP) 27.0 % 13.2 % 24.6 % 20.3 %
Adjusted Operating Profit Margin (Non-GAAP) 3 39.5 % 21.1 % 26.7 % 27.3 %
Adjusted EBITDA Margin (Non-GAAP) 4 41.5 % 23.4 % 31.2 % 30.4 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP).
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP).
DANAHER CORPORATION
Non-GAAP Profitability Measures
($ in millions)
3

-- 5 of 19 --

Three-Month Period Ended June 30, 2023
Biotechnology Life Sciences Diagnostics Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 920
Interest, Net 6
Other Nonoperating (Income) Expense 15
Income Taxes 222
Operating Profit (GAAP) $ 480 $ 340 $ 424 $ (81) $ 1,163
Other Operating Profit Adjustments 1 42 — — — 42
Amortization of Intangible Assets 218 104 50 — 372
Adjusted Operating Profit (Non-GAAP) 740 444 474 (81) 1,577
Depreciation 39 32 96 1 168
Adjusted EBITDA (Non-GAAP) $ 779 $ 476 $ 570 $ (80) $ 1,745
Interest, Net (6)
Other Nonoperating Income (Expense) (15)
Income Taxes (222)
Other Operating Profit Adjustments 1 (42)
Depreciation (168)
Amortization of Intangible Assets (372)
Net Earnings from Continuing Operations (GAAP) $ 920
Sales (GAAP) $ 1,885 $ 1,796 $ 2,231 $ 5,912
Net Earnings from Continuing Operations Margin (GAAP) 15.6 %
Operating Profit Margin (GAAP) 25.5 % 18.9 % 19.0 % 19.7 %
Adjusted Operating Profit Margin (Non-GAAP) 3 39.3 % 24.7 % 21.2 % 26.7 %
Adjusted EBITDA Margin (Non-GAAP) 4 41.3 % 26.5 % 25.5 % 29.5 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP).
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP).
DANAHER CORPORATION
Non-GAAP Profitability Measures
($ in millions)
4

-- 6 of 19 --

Six-Month Period Ended June 28, 2024
Biotechnology Life Sciences Diagnostics Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 1,995
Interest, Net 31
Other Nonoperating (Income) Expense 95
Income Taxes 359
Operating Profit (GAAP) $ 787 $ 468 $ 1,386 $ (161) $ 2,480
Other Operating Profit Adjustments 1 — 25 — — 25
Amortization of Intangible Assets 432 281 96 — 809
Adjusted Operating Profit (Non-GAAP) 1,219 774 1,482 (161) 3,314
Depreciation 77 79 197 4 357
Adjusted EBITDA (Non-GAAP) $ 1,296 $ 853 $ 1,679 $ (157) $ 3,671
Interest, Net (31)
Other Nonoperating Income (Expense) (95)
Income Taxes (359)
Other Operating Profit Adjustments 1 (25)
Depreciation (357)
Amortization of Intangible Assets (809)
Net Earnings from Continuing Operations (GAAP) $ 1,995
Sales (GAAP) $ 3,237 $ 3,515 $ 4,787 $ 11,539
Net Earnings from Continuing Operations Margin (GAAP) 17.3 %
Operating Profit Margin (GAAP) 24.3 % 13.3 % 29.0 % 21.5 %
Adjusted Operating Profit Margin (Non-GAAP) 3 37.7 % 22.0 % 31.0 % 28.7 %
Adjusted EBITDA Margin (Non-GAAP) 4 40.0 % 24.3 % 35.1 % 31.8 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP).
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP).
DANAHER CORPORATION
Non-GAAP Profitability Measures
($ in millions)
5

-- 7 of 19 --

Six-Month Period Ended June 30, 2023
Biotechnology Life Sciences Diagnostics Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 2,160
Interest, Net 24
Other Nonoperating (Income) Expense (9)
Income Taxes 505
Operating Profit (GAAP) $ 1,076 $ 661 $ 1,101 $ (158) $ 2,680
Other Operating Profit Adjustments 1 42 — — — 42
Amortization of Intangible Assets 435 209 100 — 744
Adjusted Operating Profit (Non-GAAP) 1,553 870 1,201 (158) 3,466
Depreciation 79 61 189 2 331
Adjusted EBITDA (Non-GAAP) $ 1,632 $ 931 $ 1,390 $ (156) $ 3,797
Interest, Net (24)
Other Nonoperating Income (Expense) 9
Income Taxes (505)
Other Operating Profit Adjustments 1 (42)
Depreciation (331)
Amortization of Intangible Assets (744)
Net Earnings from Continuing Operations (GAAP) $ 2,160
Sales (GAAP) $ 3,749 $ 3,505 $ 4,607 $ 11,861
Net Earnings from Continuing Operations Margin (GAAP) 18.2 %
Operating Profit Margin (GAAP) 28.7 % 18.9 % 23.9 % 22.6 %
Adjusted Operating Profit Margin (Non-GAAP) 3 41.4 % 24.8 % 26.1 % 29.2 %
Adjusted EBITDA Margin (Non-GAAP) 4 43.5 % 26.6 % 30.2 % 32.0 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP).
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP).
DANAHER CORPORATION
Non-GAAP Profitability Measures
($ in millions)
6

-- 8 of 19 --

Three-Month Period Ended June 28, 2024
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before
income taxes Income taxes
Net earnings
from continuing
operations for
calculation of
diluted earnings
per common
share
Diluted net
earnings per
common
share from
continuing
operations
Reported (GAAP) $ 5,743 $ (2,315) 59.7 % $ 1,168 20.3 % $ 1,083 $ (176) $ 907 H $ 1.22
Amortization of acquisition-related
intangible assets A — — — 402 7.0 402 402 0.54
Fair value net (gains) losses on
investments B — — — — — 59 59 0.08
Tax effect of the above adjustments E (85) (85) (0.11)
Discrete tax adjustments F (9) (9) (0.01)
Adjusted (Non-GAAP) $ 5,743 $ (2,315) 59.7 % $ 1,570 27.3 % $ 1,544 $ (270) $ 1,274 $ 1.72
Three-Month Period Ended June 28, 2024
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as
a % of sales
Nonoperating
income
(expense),
net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 5,743 $ (1,869) (32.5) % $ (391) (6.8) % $ (59) $ (26)
Amortization of acquisition-related
intangible assets A — 402 7.0 — — — —
Fair value net (gains) losses on
investments B — — — — — 59 —
Adjusted (Non-GAAP) $ 5,743 $ (1,467) (25.5) % $ (391) (6.8) % $ — $ (26)
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
7

-- 9 of 19 --

Three-Month Period Ended June 30, 2023
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before
income taxes Income taxes
Net earnings
from continuing
operations for
calculation of
diluted earnings
per common
share
Diluted net
earnings per
common
share from
continuing
operations
Reported (GAAP) $ 5,912 $ (2,594) 56.1 % $ 1,163 19.7 % $ 1,142 $ (222) $ 920 H $ 1.24
Amortization of acquisition-related
intangible assets A — — — 372 6.3 372 372 0.50
Fair value net (gains) losses on
investments B — — — — — 17 17 0.02
Impairments D — 14 0.2 42 0.7 42 42 0.06
Tax effect of the above adjustments E (82) (82) (0.11)
Discrete tax adjustments F 19 19 0.03
Rounding — — 0.1 — — — — — (0.01)
Adjusted (Non-GAAP) $ 5,912 $ (2,580) 56.4 % $ 1,577 26.7 % $ 1,573 $ (285) $ 1,288 $ 1.73
Three-Month Period Ended June 30, 2023
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as
a % of sales
Nonoperating
income
(expense),
net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 5,912 $ (1,794) (30.3) % $ (361) (6.1) % $ (15) $ (6)
Amortization of acquisition-related
intangible assets A — 372 6.3 — — — —
Fair value net (gains) losses on
investments B — — — — — 17 —
Impairments D — 28 0.5 — — — —
Rounding — — (0.1) — — — —
Adjusted (Non-GAAP) $ 5,912 $ (1,394) (23.6) % $ (361) (6.1) % $ 2 $ (6)
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
8

-- 10 of 19 --

Six-Month Period Ended June 28, 2024
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before
income taxes Income taxes
Net earnings
from continuing
operations for
calculation of
diluted earnings
per common
share
Diluted net
earnings per
common
share from
continuing
operations 5
Reported (GAAP) $ 11,539 $ (4,624) 59.9 % $ 2,480 21.5 % $ 2,354 $ (359) $ 1,995 H $ 2.68
Amortization of acquisition-related
intangible assets A — — — 809 7.0 809 809 1.09
Fair value net (gains) losses on
investments B — — — — — 96 96 0.13
Acquisition-related items C — 25 0.2 25 0.2 25 25 0.03
Tax effect of the above adjustments E (171) (171) (0.23)
Discrete tax adjustments F (45) (45) (0.06)
Rounding — — — — — — — — (0.01)
Adjusted (Non-GAAP) $ 11,539 $ (4,599) 60.1 % $ 3,314 28.7 % $ 3,284 $ (575) $ 2,709 $ 3.63
Six-Month Period Ended June 28, 2024
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as
a % of sales
Nonoperating
income
(expense),
net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 11,539 $ (3,676) (31.9) % $ (759) (6.6) % $ (95) $ (31)
Amortization of acquisition-related
intangible assets A — 809 7.0 — — — —
Fair value net (gains) losses on
investments B — — — — — 96 —
Rounding — — 0.1 — — — —
Adjusted (Non-GAAP) $ 11,539 $ (2,867) (24.8) % $ (759) (6.6) % $ 1 $ (31)
5 For the six-month period ended June 30, 2023, each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into
shares of common stock prior to their conversion on April 17, 2023. Net earnings from continuing operations per diluted common share for the relevant three-month periods may not add to the year-to-
date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
9

-- 11 of 19 --

Six-Month Period Ended June 30, 2023
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before
income taxes Income taxes
Net earnings
from continuing
operations for
calculation of
diluted earnings
per common
share
Diluted net
earnings per
common
share from
continuing
operations 5
Reported (GAAP) $ 11,861 $ (4,881) 58.8 % $ 2,680 22.6 % $ 2,665 $ (505) $ 2,139 H $ 2.89
Amortization of acquisition-related
intangible assets A — — — 744 6.3 744 744 1.00
Fair value net (gains) losses on
investments B — — — — — (5) (5) (0.01)
Impairments D — 14 0.1 42 0.4 42 42 0.06
Tax effect of the above adjustments E (145) (145) (0.19)
Discrete tax adjustments F 19 19 0.03
MCPS "as if converted" G — — — — — — — 21 —
Rounding — — 0.1 — (0.1) — — — —
Adjusted (Non-GAAP) $ 11,861 $ (4,867) 59.0 % $ 3,466 29.2 % $ 3,446 $ (631) $ 2,815 $ 3.78
Six-Month Period Ended June 30, 2023
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as
a % of sales
Nonoperating
income
(expense),
net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 11,861 $ (3,566) (30.1) % $ (734) (6.2) % $ 9 $ (24)
Amortization of acquisition-related
intangible assets A — 744 6.3 — — — —
Fair value net (gains) losses on
investments B — — — — — (5) —
Impairments D — 28 0.2 — — — —
Adjusted (Non-GAAP) $ 11,861 $ (2,794) (23.6) % $ (734) (6.2) % $ 4 $ (24)
5 For the six-month period ended June 30, 2023, each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into
shares of common stock prior to their conversion on April 17, 2023. Net earnings from continuing operations per diluted common share for the relevant three-month periods may not add to the year-to-
date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
10

-- 12 of 19 --

A Amortization of acquisition-related intangible assets in the following historical periods (only the pretax amounts set forth below are reflected in the
amortization line item above):
Three-Month Period Ended Six-Month Period Ended
June 28, 2024 June 30, 2023 June 28, 2024 June 30, 2023
Pretax $ 402 $ 372 $ 809 $ 744
After-tax 331 304 667 608
B Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods (only the pretax amounts set
forth below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended Six-Month Period Ended
June 28, 2024 June 30, 2023 June 28, 2024 June 30, 2023
Pretax $ 59 $ 17 $ 96 $ (5)
After-tax 45 13 73 (4)
C Costs incurred for the fair value adjustment to inventory related to the acquisition of Abcam plc (“Abcam”) for the six-month period ended June 28, 2024
($25 million pretax as reported in this line item, $19 million after-tax).
D Impairment charges related to technology and other assets in the Biotechnology segment recorded in the three and six-month periods ended June 30,
2023 ($42 million pretax as reported in this line item, $32 million after-tax).
E This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above
indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall
estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires
application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.
The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
F Discrete tax adjustments and other tax-related adjustments for the three-month period ended June 28, 2024, include the impact of net discrete tax benefits
of $9 million due principally to excess tax benefits from stock-based compensation. Discrete tax adjustments and other tax-related adjustments for the six-
month period ended June 28, 2024, include net discrete tax benefits of $45 million related primarily to excess tax benefits from stock-based compensation,
release of reserves for uncertain tax positions due to the expiration of statutes of limitation and changes in estimates associated with prior period uncertain
tax positions. Discrete tax adjustments and other tax-related adjustments for the three-month period ended June 30, 2023, include the impact of a net
discrete tax loss of $19 million due principally to tax costs related to the separation of the Environmental & Applied Solutions business, tax costs related to
legal and operational actions taken to realign certain businesses and changes in estimates associated with prior period uncertain tax positions, partially
offset by interest on prior year tax refunds. Discrete tax adjustments and other tax-related adjustments for the six-month period ended June 30, 2023,
include the impact of a net discrete tax loss of $19 million due principally to tax costs related to the separation of the Environmental & Applied Solutions
business, tax costs related to legal and operational actions taken to realign certain businesses and changes in estimates associated with prior period
uncertain tax positions, partially offset by excess tax benefits from stock-based compensation and interest on prior year tax refunds.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
11

-- 13 of 19 --

G In May 2020, the Company issued $1.72 billion in aggregate liquidation preference of 5.0% MCPS. Dividends on the MCPS were payable on a cumulative
basis at an annual rate of 5.0% on the liquidation preference of $1,000 per share. Each share of MCPS converted on April 17, 2023 into 5.0175 shares of
Danaher’s common stock. For the calculation of net earnings per common share from continuing operations, the impact of the dilutive MCPS is calculated
under the “if-converted” method and the related MCPS dividends are excluded. For the purposes of calculating adjusted earnings per common share from
continuing operations, the Company has excluded the paid MCPS cash dividends and assumed the “if-converted” method of share dilution (the
incremental shares of common stock deemed outstanding applying the “if-converted” method of calculating share dilution only with respect to any MCPS
the conversion of which would be dilutive in the particular period are referred to as the “Converted Shares”) for any MCPS that were anti-dilutive for the
given period. For additional information about the impact of the MCPS on the calculation of diluted EPS, see note 6 in the Average and Adjusted Average
Common Stock and Common Equivalent Diluted Shares Outstanding table below.
H Net earnings from continuing operations for calculation of diluted earnings per common share from continuing operations is summarized as follows:
Three-Month Period Ended Six-Month Period Ended
June 28, 2024 June 30, 2023 June 28, 2024 June 30, 2023
Net earnings from continuing operations $ 907 $ 920 $ 1,995 $ 2,160
MCPS dividends — — — (21)
Net earnings from continuing operations attributable to common stockholders
for Basic and Diluted EPS $ 907 $ 920 $ 1,995 $ 2,139
Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)
Three-Month Period Ended Six-Month Period Ended
June 28, 2024 June 30, 2023 June 28, 2024 June 30, 2023
Average common stock and common equivalent shares outstanding - diluted (GAAP) 6 742.4 744.7 745.5 740.2
Converted shares 7 — — — 5.1
Adjusted average common stock and common equivalent shares outstanding - diluted
(non-GAAP) 742.4 744.7 745.5 745.3
6 The impact of the MCPS calculated under the if-converted method was dilutive for the three-month period ended June 30, 2023, and as such 1.5 million shares underlying the MCPS were
included in the calculation of diluted EPS in the three-month period. The impact of the MCPS calculated under the if-converted method was anti-dilutive for the six-month period ended
June 30, 2023, and as such, 5.1 million shares underlying the MCPS were excluded from the calculation of diluted EPS and the related MCPS dividends of $21 million were included in the
calculation of net earnings for diluted EPS. There were no MCPS dividends declared in the second quarter of 2023 prior to their conversion. As of April 17, 2023, all outstanding shares of the
MCPS converted into 8.6 million shares of the Company’s common stock.
7 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using the actual conversion
rates as of June 30, 2023.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
12

-- 14 of 19 --

Segments
Total Company Biotechnology Life Sciences Diagnostics
Three-Month Period Ended June 30, 2023 Operating Profit Margins from Continuing
Operations (GAAP) 19.70 % 25.50 % 18.90 % 19.00 %
Second quarter 2024 impact from operating profit margin of businesses that has been owned
for less than one year (0.85) — (2.30) —
Second quarter 2023 impairment charges related to technology and other assets in the
Biotechnology segment 0.70 2.20 — —
Year-over-year core operating profit margin changes for the second quarter 2024 (defined
as all year-over-year operating profit margin changes other than the changes identified in
the line items above) (non-GAAP) 0.75 (0.70) (3.40) 5.60
Three-Month Period Ended June 28, 2024 Operating Profit Margins from Continuing Operations
(GAAP) 20.30 % 27.00 % 13.20 % 24.60 %
Segments
Total Company Biotechnology Life Sciences Diagnostics
Six-Month Period Ended June 30, 2023 Operating Profit Margins from Continuing
Operations (GAAP) 22.60 % 28.70 % 18.90 % 23.90 %
First half of 2024 impact from operating profit margins of businesses that have been owned
for less than one year (0.80) — (2.30) —
First half of 2024 acquisition-related fair value adjustment to inventory related to the
acquisition of Abcam (0.20) — (0.70) —
Second quarter 2023 impairment charges related to technology and other assets in the
Biotechnology segment 0.35 1.10 — —
Year-over-year core operating profit margin changes for first half of 2024 (defined as all
year-over-year operating profit margin changes other than the changes identified in the
line items above) (non-GAAP) (0.45) (5.50) (2.60) 5.10
Six-Month Period Ended June 28, 2024 Operating Profit Margins from Continuing Operations
(GAAP) 21.50 % 24.30 % 13.30 % 29.00 %
DANAHER CORPORATION
Operating Profit Margins and Year-Over-Year Core Operating Profit Margin Changes
13

-- 15 of 19 --

Three-Month Period Ended Year-over-Year
Change
Six-Month Period Ended Year-over-Year
Change	June 28, 2024 June 30, 2023 June 28, 2024 June 30, 2023
Total Cash Flow from Continuing Operations:
Net cash provided by operating activities from continuing
operations (GAAP) $ 1,417 $ 1,646 $ 3,156 $ 3,452
Total cash used in investing activities from continuing operations
(GAAP) $ (360) $ (421) $ (681) $ (716)
Total cash used in financing activities from continuing operations
(GAAP) $ (5,715) $ (208) $ (5,848) $ (470)
Free Cash Flow from Continuing Operations:
Net cash provided by operating activities from continuing
operations (GAAP) $ 1,417 $ 1,646 ~ (14.0) % $ 3,156 $ 3,452 ~ (8.5) %
Less: payments for additions to property, plant & equipment
(capital expenditures) from continuing operations (GAAP) (287) (329) (578) (595)
Plus: proceeds from sales of property, plant & equipment
(capital disposals) from continuing operations (GAAP) 1 2 1 2
Free cash flow from continuing operations (non-GAAP) $ 1,131 $ 1,319 ~ (14.5) % $ 2,579 $ 2,859 ~ (10.0) %
Operating Cash Flow from Continuing Operations to Net
Earnings from Continuing Operations Ratio (GAAP)
Net cash provided by operating activities from continuing
operations (GAAP) $ 1,417 $ 1,646 $ 3,156 $ 3,452
Net earnings from continuing operations (GAAP) 907 920 1,995 2,160
Operating cash flow from continuing operations to net earnings
from continuing operations conversion ratio 1.56 1.79 1.58 1.60
Free Cash Flow from Continuing Operations to Net
Earnings from Continuing Operations Conversion Ratio:
Free cash flow from continuing operations from above (non-
GAAP) $ 1,131 $ 1,319 $ 2,579 $ 2,859
Net earnings from continuing operations (GAAP) 907 920 1,995 2,160
Free cash flow from continuing operations to net earnings from
continuing operations conversion ratio (non-GAAP) 1.25 1.43 1.29 1.32
We define free cash flow from continuing operations as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations
(“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”).
DANAHER CORPORATION
Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations, Operating Cash Flow from Continuing Operations to Net Earnings
from Continuing Operations Ratio and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio
($ in millions)
14

-- 16 of 19 --

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure,
and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to
investors by offering additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP
measure, help our investors:
• with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to
prior and future periods and to our peers;
• with respect to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our
peers; and
• with respect to free cash flow from continuing operations and related non-GAAP cash flow measures (the “FCF Measure”), understand Danaher’s ability
to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other
strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non-
discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).
Management uses the non-GAAP measures referenced above to measure the Company’s operating and financial performance, and uses core sales and non-
GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company’s executive
compensation program.
• The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
◦ Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such
charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of
significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to
intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion
of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held
businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand
that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future
periods until such intangible assets have been fully amortized.
◦ Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size,
strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that
result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the
ordinary course of our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs
to facilitate a more consistent comparison of operating results over time.
◦ Other Adjustments: With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing
Operations, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may
be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends
and make comparisons of long-term performance difficult.
• With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s MCPS mandatorily converted into Danaher
common stock on the mandatory conversion date of April 17, 2023 (unless converted or redeemed earlier in accordance with the terms of the applicable
certificate of designations). With respect to the calculation of Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we apply the
“if converted” method of share dilution to the MCPS in all applicable periods irrespective of whether such preferred shares would be dilutive or anti-dilutive
in the period. We believe this presentation provides useful information to investors by helping them understand the net impact on Danaher’s earnings per
share-related measures irrespective of the period.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
15

-- 17 of 19 --

• With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to "restructuring charges” and
“other adjustments”, we exclude the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued
operations) because the timing, size, number and nature of such transactions can vary significantly from period to period and may obscure underlying
business trends and make comparisons of long-term performance difficult.
• We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in
the applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps
our investors compare the profitability of our individual segments to peer companies with like business lines.
• With respect to core sales, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to volatility and can
obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature
of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends
and make comparisons of long-term performance difficult.
• With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to
demonstrate the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.
The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue,
such as currency translation, acquisitions and divested product lines. Additionally, we do not reconcile forecasted adjusted operating profit margin (or components
thereof) to the comparable GAAP measures because of the difficulty in estimating the other components (in addition to items identified in the prior sentence) such
as investment gains and losses and impairments, which would be reflected in any forecasted GAAP operating profit.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
16

-- 18 of 19 --

17

-- 19 of 19 --